Dr. Jeffrey A. Bubis, DO
Medical Oncology (Medical Oncology Physician)
4689 Us Highway 17 Ste 2-5
Fleming Island, FL 32003
Who else practices at this address →
Clay County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 599
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Philadelphia College of Osteopathic Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license OS9446 -
Hematology (Internal Medicine) Physician
FL license OS9446
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Adventhealth PAlm Coast Palm Coast, FL
- HCA Florida Orange PArk Hospital Orange PArk, FL
- Ascension St Vincent's Clay County Middleburg, FL
- Ascension St Vincent's St Johns County St. Johns, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 599
- Services billed
- 139,264
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, aprepitant, 1 mg | 7,670 | 17 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 6,380 | 19 |
| Injection, ferric derisomaltose, 10 mg | 4,800 | 28 |
| Injection, denosumab, 1 mg | 2,700 | 34 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,910 | 27 |
| Insertion of needle into vein for collection of blood sample | 1,221 | 321 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,105 | 285 |
| Established patient office or other outpatient visit, 20-29 minutes | 635 | 333 |
| Injection, palonosetron hcl, 25 mcg | 570 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 504 | 174 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Fleming Island, FL | 101 |
| Anastrozole Other prescribers in Fleming Island, FL | 85 |
| Prochlorperazine Maleate Other prescribers in Fleming Island, FL | 65 |
| Ondansetron Hcl Other prescribers in Fleming Island, FL | 49 |
| Dexamethasone Other prescribers in Fleming Island, FL | 41 |
| Gabapentin Other prescribers in Fleming Island, FL | 41 |
| Oxycodone Hcl Other prescribers in Fleming Island, FL | 39 |
| Prednisone Other prescribers in Fleming Island, FL | 35 |
| Brukinsa (zanubrutinib) | 32 |
| Hydroxyurea Other prescribers in Fleming Island, FL | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 75 payments worth $11,781 in total to this clinician.
| Janssen Biotech, Inc. | $4,650 |
|---|---|
| GlaxoSmithKline, LLC. | $3,354 |
| AstraZeneca Pharmaceuticals LP | $1,731 |
| Tersera Therapeutics LLC | $804 |
| Novartis Pharmaceuticals Corporation | $235 |
| Pfizer Inc. | $120 |
| Merck Sharp & Dohme LLC | $86.39 |
| Regeneron Healthcare Solutions, Inc. | $78.89 |
| Consulting Fee | $10,053 |
|---|---|
| Food and Beverage | $1,464 |
| Travel and Lodging | $250 |
| Education | $15.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 14, 2025 | Consulting Fee TALVEY; TECVAYLI; CARVYKTI · Oncology | $4,400 |
| GlaxoSmithKline, LLC. Jun 12, 2025 | Consulting Fee | $3,263 |
| AstraZeneca Pharmaceuticals LP Jun 5, 2025 | Consulting Fee IMFINZI · Oncology | $1,640 |
| Tersera Therapeutics LLC Jan 27, 2025 | Consulting Fee | $750 |
| Janssen Biotech, Inc. Nov 14, 2025 | Travel and Lodging TALVEY; TECVAYLI; CARVYKTI · Oncology · travel to ATLANTA, GA | $250 |
| Amgen Inc. Sep 24, 2025 | Education in-kind | $15.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $144,523 in research payments for these studies, mostly to the institutions running them.
- Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junctio…
AstraZeneca Pharmaceuticals LP - A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia i…
Novartis Pharmaceuticals Corporation - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca Pharmaceuticals LP - An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Beone Medicines USA, Inc. · Completed · NCT04047862
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.